Charles Lunn
Family Medicine · Oklahoma City, OKNPI 1477529535
Payments from drug & device makers
Across 392 payments — averaging $3697.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$415K
- AstraZeneca$371K
- Sanofi US Services Inc.$163K
- Amgen$143K
- Bavarian Nordic A/s$92K
- AbbVie$91K
- plus $176K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 38 | $414,722 |
| AstraZeneca | 11 | $370,888 |
| Sanofi US Services Inc. | 125 | $162,591 |
| Amgen | 8 | $142,714 |
| Bavarian Nordic A/s | 38 | $91,555 |
| AbbVie(2 entities) | 66 | $90,674 |
| Kowa Research Institute, Inc. | 49 | $68,682 |
| Alnylam Pharmaceuticals Inc. | 7 | $55,704 |
| Astrazeneca UK Limited | 2 | $21,891 |
| Eli Lilly | 3 | $11,912 |
| Esperion Therapeutics, Inc. | 7 | $6,530 |
| Sanofi Pasteur Inc. | 1 | $5,000 |
| Shionogi Inc | 1 | $4,729 |
| Lexicon Pharmaceuticals, Inc. | 1 | $1,061 |
| Novo Nordisk | 16 | $285 |
| Boehringer Ingelheim | 3 | $70 |
| Lilly USA, LLC | 3 | $54 |
| GSK | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Mylan Specialty L.p. | 1 | $21 |
| Pfizer | 1 | $20 |
| Abbott | 1 | $20 |
| Recor Medical Inc | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
How this compares
$1,449,288 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
- Jonathon KnoxOklahoma City$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.